MONAS
FINANCIAL
Home
About
Research
Data
Pricing
Team
News
Analysis
Press
Contact
Legal
← News
Morgan Stanley Maintains Overweight on Merck & Co, Lowers Price Target to $177
Analyst Ratings
MRK
Oct 7
AI-curated analysis for informational purposes only — not investment advice.
Morgan Stanley Maintains Overweight on Merck & Co, Lowers Price Target to $177
Read the full story at benzinga.com →